256 studies found for:    Open Studies | "Hodgkin Disease"
Show Display Options
Rank Status Study
21 Recruiting Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma
Condition: Hodgkin Disease
Intervention: Drug: Lenalidomide
22 Recruiting Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205)
Condition: Hodgkin Disease
Intervention: Drug: Nivolumab
23 Recruiting Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Conditions: Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: Adcetris;   Drug: Bendamustine
24 Recruiting Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: Temsirolimus
25 Recruiting Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
Conditions: Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis
26 Recruiting Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Adult Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis
27 Recruiting Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: doxorubicin;   Drug: bleomycin;   Drug: vinblastine;   Drug: dacarbazine
28 Unknown  Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
Condition: Hodgkin's Lymphoma
Intervention: Drug: Oxaliplatin-based chemotherapy (ESHAOx)
29 Recruiting Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
30 Recruiting Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
Condition: Hodgkins Lymphoma
Intervention: Biological: allogeneic donor derived LMP specific cytotoxic T-lymphocyte
31 Recruiting Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Condition: Hodgkin Lymphoma, Adult
Interventions: Drug: Brentuximab vedotin;   Drug: ABVD
32 Recruiting HD17 for Intermediate Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone);   Drug: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine);   Radiation: 30Gy IF-RT (Involved-Field Radiotherapy);   Radiation: 30Gy IN-RT (Involved-Node Radiotherapy)
33 Recruiting HD16 for Early Stage Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine);   Radiation: 20 Gy IFRT (Involved Field Radiotherapy)
34 Recruiting Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: dose dense ABVD
35 Unknown  IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: IGEV
36 Recruiting Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL
Conditions: Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma
Intervention: Drug: Pembrolizumab
37 Recruiting GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: AFM13
38 Recruiting Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Stanford V Chemotherapy;   Radiation: Radiation Therapy
39 Unknown  Consolidation PET-based and Donor-based After Salvage Therapy in Patients With Hodgkin Lymphoma in Relapse or Refractory
Condition: Hodgkin's Lymphoma
Interventions: Other: Patients with negative PET after salvage therapy;   Other: Patients with positive PET after salvage therapy
40 Recruiting Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Conditions: Hodgkin Lymphoma;   Diffuse Large B-cell Lymphoma
Interventions: Biological: campath;   Biological: Rituximab;   Drug: EPOCH

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years